Skip to main content
Scientist talking at a podium to group at a conference.
Working with Us

2022 PD Therapeutics Conference

  • Register
About the Conference
Male speaker at podium for the 2017 Parkinson's Disease Therapeutics Conference

*Please note that everyone must be fully vaccinated against COVID-19 in order to attend this meeting. You will be required to show proof of vaccination status at the door.

The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development. The 14th Annual PD Therapeutics Conference is scheduled to be held on October 13, 2022, in-person, in New York.

Each year, the PD Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from MJFF's research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.

REGISTER HERE (Registration closes Tuesday, October 11 at 5 P.M. EST)

For Questions or Updates,

Please contact researchmeetings@michaeljfox.org.


Sponsor logos
Conference Schedule (subject to change)
7:45
BREAKFAST
8:30-8:45
WELCOME
Speakers: Sohini Chowdhury, Deputy CEO, The Michael J. Fox Foundation
8:45-10:30
ADVANCES IN PARKINSON’S THERAPEUTIC DEVELOPMENT
Session Introduction: "The Parkinson’s Disease Therapeutic Landscape - Today and Tomorrow"
Speakers: Brian Fiske, PhD, Co-Chief Scientific Officer, The Michael J. Fox Foundation
"A Novel Therapeutic Strategy for Rescuing Neurons from Mitochondrial Dysfunction in PD"
Speakers: Roland Staal, PhD, Director of Pharmacology, Lucy Therapeutics
"Addressing the Cholinergic Deficit in Parkinson's Disease"
Arthur A. Simen, MD, PhD, Executive Medical Director, Takeda Development Center Americas
"Developing a PPMI Prodromal PD Cohort for Disease Prevention"
Ken Marek, MD, President, Institute for Neurodegenerative Disorders
Fireside Chat: "Building Hope in the Parkinson's Pipeline"
Facilitator: Brian Fiske, PhD; Panelists: Stacie Weninger, PhD; Kevin McFarthing, PhD
10:30-10:50
NETWORKING BREAK / POSTER VIEWING
10:50-:12:00
ADVANCES IN EXISTING AND EMERGING ENDPOINTS (PART 1)
Session Introduction: "Diagnostic and Progression Biomarkers to Accelerate All Therapeutic Programs"
Mark Frasier, PhD, Co-Chief Scientific Officer, The Michael J. Fox Foundation
"PD Biomarker Vanguard: a-Synuclein Seed Amplification Assay"
Lana Chahine, MD, Assistant Professor of Neurology, University of Pittsburgh
"Imaging Biomarkers in PD Therapeutic Trials: Where We are Now and Where We are Going?"
John Seibyl, MD, Co-Founder & Chairman, Institute for Neurodegenerative Disorders
"Digital Health Technologies in PD Therapeutic Development: State of the Art"
Josh Cosman, Director, Digital Health Strategy, AbbVie
12:00-1:15
LUNCH / POSTER VIEWING
1:15 - 2:45
ADVANCES IN EXISTING AND EMERGING ENDPOINTS (PART 2)
Session Introduction: "Tools to Measure Meaningful Change"
Mark Frasier, PhD, Co-Chief Scientific Officer, The Michael J. Fox Foundation
"Patient-Centered Clinical Outcomes Assessments"
Glenn Stebbins, PhD, Professor Emeritus, Rush University Medical Center
"Slowing Progression of Parkinson's Disease. Are We Closer to the Finish Line? How Better Outcomes will Advance TX"
Tanya Simuni, MD, Arthur C. Nielsen Jr. Professor of Neurology; Director, Parkinson's Disease and Movement Disorders Center, Northwestern University, Feinberg School of Medicine
Panel: "Blueprints for Breakthroughs: How Better Endpoints Will Drive Future PD Trial Design"
Facilitator: Catherine Kopil, PhD; Panelists: Mark Frasier, PhD; Lana Chahine, MD; John Seibyl, MD; Josh Cosman; Glenn Stebbins, PhD; Tanya Simuni, MD
2:45-3:00
NETWORKING BREAK / POSTER VIEWING
3:00-4:20
EMERGING TARGETS AND APPROACHES FOR TARGET IDENTIFICATION
Session Introduction: "A Primer on the Landscape of Emerging PD Targets"
Shalini Padmanabhan, PhD, Vice President, The Michael J. Fox Foundation
"Proteogenomics in Parkinson's Disease: Implications for Precision Medicine"
Fiona Elwood, PhD, Vice President Neurodegeneration Disease; Area Stronghold Leader, Janssen Pharmaceuticals
"Genetic Targets for PD Drug Development"
Nicholas Wood, MbChB, PhD, FRCP, FMedSci, University College London Queen Square Institute of Neurology
Panel: "How Can We Prioritize and Validate Targets for PD Therapeutic Development?"
Facilitator: Shalini Padmanabhan, PhD; Panelists: Fiona Elwood, PhD; Nicholas Wood, MbChB, PhD, FRCP, FMedSci; Manuela Polydoro, PhD; Jim Sullivan, PhD
4:20-4:40
SPECIAL GUEST PRESENTATION AND Q&A
Jimmy Choi, MJFF Patient Council Member
4:40-4:45
CLOSING REMARKS
4:45-6:00
COCKTAIL RECEPTION / POSTER VIEWING
Speakers

Sohini Chowdhury, Deputy CEO |The Michael J. Fox Foundation 

Brian Fiske, PhD, Co-Chief Scientific Officer | The Michael J. Fox Foundation 

Roland Staal, PhD, Director of Pharmacology | Lucy Therapeutics 

Arthur A. Simen, MD, PhD, Executive Medical Director | Takeda Development Center Americas

Kenneth Marek, MD, President | Institute for Neurodegenerative Disorders 

Stacie Weninger, PhD, President | FBRI 

Kevin McFarthing, PhD | Research Advocate  

Mark Frasier, PhD, Co-Chief Scientific Officer | The Michael J. Fox Foundation 

Lana Chahine, MD, Assistant Professor of Neurology | University of Pittsburgh 

John Seibyl, MD, Co-Founder & Chairman | Institute for Neurodegenerative Disorders 

Josh Cosman, Director, Digital Health Strategy | AbbVie 

Glenn Stebbins, PhD, Professor Emeritus | Rush University Medical Center 

Tanya Simuni, MD | Arthur C. Nielsen Jr. Professor of Neurology | Director, Parkinson’s Disease and Movement Disorders Center | Northwestern University Feinberg School of Medicine 

Catherine Kopil, PhD, Senior Vice President | The Michael J. Fox Foundation 

Shalini Padmanabhan, PhD, Vice President | The Michael J. Fox Foundation 

Fiona Elwood, PhD, Vice President Neurodegeneration Disease Area Stronghold Leader | Janssen Pharmaceuticals

Nicholas Wood, MbChB, PhD, FRCP, FMedSci | UCL Queen Square Institute of Neurology 

Manuela Polydoro, PhD, Head of Translational Medicine | Muna Therapeutics 

Jim Sullivan, PhD,  Co-Founder & CEO| Vanqua Bio, Venture Partner, OrbiMed 

Jimmy Choi | Patient Council Member, The Michael J. Fox Foundation

 

Posters
  • Posters

    Identification and Evaluation of Novel Imaging Probes for Alpha Synuclein Aggregates by DNA-Encoded Library Screening 

    Changning Wang, PhD

    Assistant Professor of Radiology

    Athinoula A. Martinos Center for Biomedical Imaging

    Massachusetts General Hospitals

    Harvard Medical School

     

    Imaging Studies in Parkin Patients and Advancement of Parkin Gene Therapy 

    Jennifer A. Johnston 

    CEO 

    NysnoBio 

     

    Advancing TRPML1 Agonists for GBA-PD 

    Magdalene Moran, PhD 

    President & Chief Scientific Officer 

    Caraway Therapeutics 

     

    Associations of Reduced Caffeine Exposure with PD and Reduced GCase Activity with GBA Carrier Status: A Metabolomic Biomarker Study in PPMI Plasma 

    Sarah Huntwork- Rodriguez, PhD 

    Director, Senior Scientist, Translational Sciences 

    Denali Therapeutics 

     

    Small Molecule PINK1 Activators Rescue Parkinson’s Disease Pathology 

    Nicholas Hertz, PhD 

    Chief Scientific Officer & Co-Founder 

    Mitokinin Inc. 

     

    Ultrasensitive 24h- Semi-Quantitative Seed Amplification Assay for the Accurate Differentiation between MSA and LBD 

    Luis Concha, PhD 

    Director of Research & Development 

    Amprion Inc. 

Conference Sponsors
Sponsor logos

Interested in Sponsorship Opportunities?

Contact our Research Alliances team at researchpartnerships@michaeljfox.org for information about 2022 sponsorship opportunities. 

About the Venue

Address

Convene Conference Center
117 W 46th St 
New York, NY 10036

Speaker on stage with panelists at the Parkinson's Disease Therapeutics Conference.

Convene at 117 West 46th Street is our largest event venue in Midtown West Manhattan. Located between Times Square and Rockefeller Center, it’s the ideal space (up to 600 guests) for your next summit, awards dinner, town hall, or gala. As one of Convene's flagship properties, this space offers "white-box" design capability. Professional meeting planners are provided with the ability to customize the space with multiple sponsor and corporate branding opportunities with our digital video walls, physical exhibit areas, columns, and walls.

*Please note that Convene requires all attendees and staff to be fully vaccinated against COVID-19 in order to attend a meeting at their facility. You will be required to show proof of vaccination status at the door.


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.